Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors

Detalhes bibliográficos
Autor(a) principal: Rodrigo Dos Santos Horta
Data de Publicação: 2018
Outros Autores: Antonio Giuliano, Gleidice Eunice Lavalle, Mariana de Pádua Costa, Roberto Baracat de Araújo, Fernando Constantino Casas, Jane Margaret Dobson
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFMG
Texto Completo: http://hdl.handle.net/1843/42628
Resumo: The aim of the present prospective-retrospective study was to evaluate the response of high‑risk canine mast cell tumours (MCTs) to tyrosine kinase inhibitors (TKIs) and to correlate this with prognostic factors. A total of 24 dogs presented with macroscopic cutaneous MCTs at disease stage II or III, and therefore, at high‑risk of associated mortality, were included in the study and treated with masitinib (n=20) or toceranib (n=4). A total of 12/24 dogs achieved an objective response and the overall survival (OS) for all subjects was 113 days. Dogs responding to treatment had a significant increase in OS compared to non‑responders (146.5 days vs. 47 days, P=0.02). Internal tandem duplications in exon 11 of the c‑kit gene were identified in 6/24 cases. Ki67, KIT immunolabelling and c‑kit mutation did not provide information regarding prognosis or prediction of response to TKIs in this population. Initial response to TKIs appears to be the most reliable prognostic factor for survival duration.
id UFMG_f2fad29909a567136f3d251bf0cf95d8
oai_identifier_str oai:repositorio.ufmg.br:1843/42628
network_acronym_str UFMG
network_name_str Repositório Institucional da UFMG
repository_id_str
spelling 2022-06-23T21:44:22Z2022-06-23T21:44:22Z2018151291361792-1074http://hdl.handle.net/1843/42628The aim of the present prospective-retrospective study was to evaluate the response of high‑risk canine mast cell tumours (MCTs) to tyrosine kinase inhibitors (TKIs) and to correlate this with prognostic factors. A total of 24 dogs presented with macroscopic cutaneous MCTs at disease stage II or III, and therefore, at high‑risk of associated mortality, were included in the study and treated with masitinib (n=20) or toceranib (n=4). A total of 12/24 dogs achieved an objective response and the overall survival (OS) for all subjects was 113 days. Dogs responding to treatment had a significant increase in OS compared to non‑responders (146.5 days vs. 47 days, P=0.02). Internal tandem duplications in exon 11 of the c‑kit gene were identified in 6/24 cases. Ki67, KIT immunolabelling and c‑kit mutation did not provide information regarding prognosis or prediction of response to TKIs in this population. Initial response to TKIs appears to be the most reliable prognostic factor for survival duration.O objetivo do presente estudo prospectivo-retrospectivo foi avaliar a resposta dos mastocitomas caninos (MCTs) de alto risco aos inibidores da tirosina quinase (TKIs) e correlacioná-la com fatores prognósticos. Um total de 24 cães apresentavam MCTs cutâneos macroscópicos em estágio II ou III da doença e, portanto, com alto risco de mortalidade associada, foram incluídos no estudo e tratados com masitinibe (n=20) ou toceranibe (n=4). Um total de 12/24 cães alcançou uma resposta objetiva e a sobrevida global (OS) para todos os indivíduos foi de 113 dias. Os cães que responderam ao tratamento tiveram um aumento significativo na SG em comparação com os não respondedores (146,5 dias vs. 47 dias, P=0,02). Duplicações em tandem internas no exon 11 do gene c-kit foram identificadas em 6/24 casos. Ki67, imunomarcação KIT e mutação c-kit não forneceram informações sobre prognóstico ou previsão de resposta a TKIs nesta população. A resposta inicial aos TKIs parece ser o fator prognóstico mais confiável para a duração da sobrevida.engUniversidade Federal de Minas GeraisUFMGBrasilVET - DEPARTAMENTO DE CLÍNICA E CIRURGIAOncology lettersCachorroCâncerMasitinibePrednisolonaToceranibeC-kitClinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitorsFatores clínicos, histológicos, imuno-histoquímicos e genéticos associados à resposta mensurável de mastocitomas caninos de alto risco a inibidores de tirosina quinaseinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://www.spandidos-publications.com/10.3892/ol.2017.7323Rodrigo Dos Santos HortaAntonio GiulianoGleidice Eunice LavalleMariana de Pádua CostaRoberto Baracat de AraújoFernando Constantino CasasJane Margaret Dobsonapplication/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLICENSELicense.txtLicense.txttext/plain; charset=utf-82042https://repositorio.ufmg.br/bitstream/1843/42628/1/License.txtfa505098d172de0bc8864fc1287ffe22MD51ORIGINAL2018_Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors.pdf2018_Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors.pdfapplication/pdf1026573https://repositorio.ufmg.br/bitstream/1843/42628/2/2018_Clinical%2c%20histological%2c%20immunohistochemical%20and%20genetic%20factors%20associated%20with%20measurable%20response%20of%20high-risk%20canine%20mast%20cell%20tumours%20to%20tyrosine%20kinase%20inhibitors.pdf203ba46aafef1f31a4e6dc86043d811eMD521843/426282022-06-23 18:44:23.134oai:repositorio.ufmg.br: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Repositório de PublicaçõesPUBhttps://repositorio.ufmg.br/oaiopendoar:2022-06-23T21:44:23Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false
dc.title.pt_BR.fl_str_mv Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors
dc.title.alternative.pt_BR.fl_str_mv Fatores clínicos, histológicos, imuno-histoquímicos e genéticos associados à resposta mensurável de mastocitomas caninos de alto risco a inibidores de tirosina quinase
title Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors
spellingShingle Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors
Rodrigo Dos Santos Horta
Cachorro
Câncer
Masitinibe
Prednisolona
Toceranibe
C-kit
title_short Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors
title_full Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors
title_fullStr Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors
title_full_unstemmed Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors
title_sort Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors
author Rodrigo Dos Santos Horta
author_facet Rodrigo Dos Santos Horta
Antonio Giuliano
Gleidice Eunice Lavalle
Mariana de Pádua Costa
Roberto Baracat de Araújo
Fernando Constantino Casas
Jane Margaret Dobson
author_role author
author2 Antonio Giuliano
Gleidice Eunice Lavalle
Mariana de Pádua Costa
Roberto Baracat de Araújo
Fernando Constantino Casas
Jane Margaret Dobson
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Rodrigo Dos Santos Horta
Antonio Giuliano
Gleidice Eunice Lavalle
Mariana de Pádua Costa
Roberto Baracat de Araújo
Fernando Constantino Casas
Jane Margaret Dobson
dc.subject.other.pt_BR.fl_str_mv Cachorro
Câncer
Masitinibe
Prednisolona
Toceranibe
C-kit
topic Cachorro
Câncer
Masitinibe
Prednisolona
Toceranibe
C-kit
description The aim of the present prospective-retrospective study was to evaluate the response of high‑risk canine mast cell tumours (MCTs) to tyrosine kinase inhibitors (TKIs) and to correlate this with prognostic factors. A total of 24 dogs presented with macroscopic cutaneous MCTs at disease stage II or III, and therefore, at high‑risk of associated mortality, were included in the study and treated with masitinib (n=20) or toceranib (n=4). A total of 12/24 dogs achieved an objective response and the overall survival (OS) for all subjects was 113 days. Dogs responding to treatment had a significant increase in OS compared to non‑responders (146.5 days vs. 47 days, P=0.02). Internal tandem duplications in exon 11 of the c‑kit gene were identified in 6/24 cases. Ki67, KIT immunolabelling and c‑kit mutation did not provide information regarding prognosis or prediction of response to TKIs in this population. Initial response to TKIs appears to be the most reliable prognostic factor for survival duration.
publishDate 2018
dc.date.issued.fl_str_mv 2018
dc.date.accessioned.fl_str_mv 2022-06-23T21:44:22Z
dc.date.available.fl_str_mv 2022-06-23T21:44:22Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/1843/42628
dc.identifier.issn.pt_BR.fl_str_mv 1792-1074
identifier_str_mv 1792-1074
url http://hdl.handle.net/1843/42628
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Oncology letters
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Minas Gerais
dc.publisher.initials.fl_str_mv UFMG
dc.publisher.country.fl_str_mv Brasil
dc.publisher.department.fl_str_mv VET - DEPARTAMENTO DE CLÍNICA E CIRURGIA
publisher.none.fl_str_mv Universidade Federal de Minas Gerais
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFMG
instname:Universidade Federal de Minas Gerais (UFMG)
instacron:UFMG
instname_str Universidade Federal de Minas Gerais (UFMG)
instacron_str UFMG
institution UFMG
reponame_str Repositório Institucional da UFMG
collection Repositório Institucional da UFMG
bitstream.url.fl_str_mv https://repositorio.ufmg.br/bitstream/1843/42628/1/License.txt
https://repositorio.ufmg.br/bitstream/1843/42628/2/2018_Clinical%2c%20histological%2c%20immunohistochemical%20and%20genetic%20factors%20associated%20with%20measurable%20response%20of%20high-risk%20canine%20mast%20cell%20tumours%20to%20tyrosine%20kinase%20inhibitors.pdf
bitstream.checksum.fl_str_mv fa505098d172de0bc8864fc1287ffe22
203ba46aafef1f31a4e6dc86043d811e
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)
repository.mail.fl_str_mv
_version_ 1803589558191783936

Registros relacionados